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Abstract Spalax ehrenbergi has evolved adaptations that allow
it to survive and carry out normal activities in a highly hypoxic
environment. A key component of this adaptation is a higher
capillary density in some Spalax tissues resulting in a shorter
diffusion distance for oxygen. Vascular endothelial growth factor
(VEGF) is an angiogenic factor that is critical for angiogenesis
during development and in response to tissue ischemia. We
demonstrate here that VEGF expression is markedly increased in
those Spalax tissues with a higher capillary density relative to the
normal laboratory rat Rattus norvegicus. Upregulation of VEGF
thus appears to be an additional mechanism by which Spalax has
adapted to its hypoxic environment.
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1. Introduction
Subterranean mammals have evolved a unique set of struc-
tural and functional modi¢cations of their cardiovascular and
respiratory systems that insure a successful adaptation to this
extreme environment for prolonged periods of time. Nevo and
colleagues over the past 30 years have used as a model for
understanding these adaptations one such subterranean mam-
mal, the mole rat Spalax ehrenbergi [1]. The critical PO2 (the
lowest oxygen pressure supporting life) is lower for Spalax
than for any other rodent studied to date. This capacity to
withstand hypoxic conditions even exceeds that manifested by
many high altitude and diving mammals [2^11].
The superspecies Spalax ehrenbergi, belonging to the family
Spalacidae, includes in Israel four biological species that di¡er
not only in their chromosomal number (2n = 52, 54, 58 and
60) but also their habitat [1]. Spalax lives predominately in
underground tunnels in which the oxygen tension is often
severely reduced. A number of strategies that are used by
Spalax to tolerate this environment have been elucidated.
First, Spalax can achieve a higher myocardial maximal oxy-
gen consumption under hypoxic conditions [12,13]. Second,
Spalax demonstrates structural adaptations in tissues such
as skeletal muscle that result in a reduction in the di¡usion
distance of oxygen to the mitochondria and permit e⁄cient
oxygen delivery even at low capillary PO2 [12,14]. These adap-
tations consist of a signi¢cant increase in both the mitochon-
drial density and the capillary density. Third, there is a
marked increase in Spalax lung di¡usion capacity which per-
mits the continued oxygenation of blood to occur in Spalax
lung even in the presence of a decreased inspired PO2 [3,14^
17]. Fourth, speci¢c di¡erences in the abundance of molecules
such as myoglobin which augment oxygen delivery particu-
larly at low oxygen tensions have been demonstrated [3,18].
Fifth, the blood properties of Spalax have been reported to be
adapted to facilitate O2 transport in burrowing atmospheres
via increases in the erythrocyte count [8], reduction in the
mean corpuscular volume [14], and changes in the 2,3-diphos-
phoglycerate:hemoglobin ratio [2]. Finally, the primary struc-
tures of Spalax hemoglobin [19,20], haptoglobin [21] and my-
oglobin [22] display many amino acid substitutions as
compared with other rodents, albeit the e¡ect of these sub-
stitutions on the function of these molecules and their contri-
bution to ¢tness are unknown. Signi¢cantly for the study of
these adaptations, Nevo et al. [23] have shown in di¡erential
survivorship studies that the four chromosomal species of
Spalax do not undergo acclimatization upon transfer from
their natural habitat to a standardized laboratory environ-
ment but rather behave di¡erentially according to their eco-
geographic origins.
Recently, Widmer et al. [13] have incorporated these data
into a hypothesis that the capacity of Spalax to do aerobic
work under low O2 pressures is due in large part to adapta-
tions in the structural design of the cardiorespiratory system.
A key component of these adaptations as mentioned above is
a higher capillary density which results in a shorter di¡usion
distance for oxygen to the mitochondria. The molecular basis
for this increased blood vessel density, speci¢cally in Spalax
skeletal muscle, is not understood.
Vascular endothelial growth factor (VEGF) is a potent an-
giogenic factor that is critical for angiogenesis during develop-
ment [24] and in response to tissue hypoxia [25]. We and
others have previously shown that the regulation of VEGF
by hypoxia occurs at the level of its steady-state mRNA [25^
30]. Therefore, in order to understand the molecular basis for
the increased capillary density of Spalax we studied the regu-
lation of VEGF mRNA in three species (2n = 52, 58 and 60)
of the subterranean superspecies Spalax ehrenbergi as com-
pared to the normal laboratory white rat Rattus norvegicus.
We have cloned and characterized Spalax VEGF, measured
blood vessel density in Spalax and Rattus tissues, and have
quantitated VEGF mRNA in Spalax and Rattus tissues under
a variety of conditions of graded hypoxia. Taken together our
¢ndings suggest an additional molecular mechanism for the
hypoxic tolerance of Spalax through an increase in the angio-
genic factor VEGF.
0014-5793 / 99 / $20.00 ß 1999 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 9 9 ) 0 0 5 8 4 - 0
*Corresponding author. Fax: (972) (4) 8246554.
E-mail: rabi301@uvm.ac.il
FEBS 22044 7-6-99 Cyaan Magenta Geel Zwart
FEBS 22044 FEBS Letters 452 (1999) 133^140
2. Materials and methods
2.1. Animals
The study was carried out on white rats (Rattus norvegicus) and
subterranean mole rats (Spalax ehrenbergi). The chromosomal species
characteristics of the di¡erent species of Spalax ehrenbergi have been
previously described and include 2n = 52, 2n = 58 and 2n = 60 [1]. The
2n = 52 were from the Kerem Ben Zimra population, the 2n = 58 were
from the Mount Carmel Mukhraka population and the 2n = 60 were
from the Anza Samaria population. A total of six Rattus and six
Spalax from each of the three chromosomal species were used in these
studies. Animals were housed in individual cages, kept under con-
trolled conditions of 22^24‡C with seasonal light/dark hours. The
Spalax used in these experiments were hunted in the ¢eld and kept
in the animal house for 3^6 months. All animals used in this study
were adults and of similar weight (100^150 g). Hypoxia was achieved
by incubating the animals in a sealed 70U70U50 cm chamber divided
into separate cells into which de¢ned O2 or O2/CO2 mixtures were
delivered at a £ow rate of 3.5 l/min. The gas mixturours.
2.2. Tissue sampling
Animals were killed by intramuscular injection of Imalgene 100
(100 mg/ml ketamine, 5 mg/kg body weight injection, Rhone-Merieux,
France). Tissue was immediately extracted and frozen in liquid nitro-
gen (for RNA analysis) or placed in 10% bu¡ered formalin for mor-
phometric analysis. For molecular analysis skeletal muscle (rhombo-
ideus capitis) or whole brain was used. For morphometric analysis
skeletal muscle (rhomboideus capitis) or speci¢c brain sections from
cerebral cortex, white matter, hippocampus and cerebellar cortex were
studied.
2.3. Microvessel quantitation
Skeletal muscle and brain microvascularity were determined by
Fig. 1. A: Nucleotide and amino acid sequence of Spalax ehrenbergi (2n = 52) for the VEGF 165 amino acid isoform. Primers used for RT-
PCR are underlined. B: Comparison of the amino acid sequence of Spalax ehrenbergi (2n = 52) VEGF 165 amino acid isoform with that from
other species. The PRETTYBOX program from GCG software was used to determine the proper alignment. Black background indicates con-
sensus sequence. White background marks non-conservative amino acid shift. Gray-stripped background marks conservative changes.
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quantifying the density of capillary structures [13]. Capillary struc-
tures were identi¢ed immunohistochemically by staining with factor
VIII-related antigen. Evaluation of vascularity was performed in mi-
croscopic ¢elds where the myo¢brils were sectioned transversely. Rep-
resentative sections of cerebral cortex (temporal lobe), white matter
(temporal lobe), hippocampus and cerebellar cortex were evaluated. A
single microvessel was de¢ned as any immunostained endothelial cell
that was separated from adjacent microvessels, other cell types or
connective tissue elements. The number of vessel pro¢les was counted
at 400U magni¢cation. The area of ¢eld of vision at this magni¢ca-
tion is 0.55 mm. Six ¢elds were counted for each tissue sample and the
average number of counts was recorded as vessels per high power
¢eld.
2.4. Immunohistochemical methods
Sections from formalin-¢xed para⁄n-embedded tissue blocks were
cut at 5 Wm, depara⁄nized and dehydrated with xylene and graded
alcohol. Microwave/pressure cooker pretreatment (two cycles of 10
min each) was performed in 10 mM citrate bu¡er (pH 6.0). Endoge-
nous peroxidase activity was quenched with 3% hydrogen peroxide at
room temperature for 10 min. Sections were blocked with 10% goat
serum for 30 min and then incubated with polyclonal rabbit anti-
factor VIII-related antigen (EURODPC, Gwynedd, UK) for 1 h at
room temperature. The labeled streptavidin-biotin-peroxidase method
using the Histostain-Plus kit and AEC substrate from Zymed Labo-
ratories (South San Francisco, CA, USA) was employed. Light coun-
terstaining was performed with hematoxylin.
2.5. Isolation and sequencing of Spalax VEGF cDNA
Total RNA was prepared from Spalax 2n = 52 brain using RNA-
clean system (Angewandte Gentechnologie, Heidelberg, Germany).
First strand cDNA was prepared with oligo dT and reverse transcrip-
tase (BRL, USA) and subsequently used in a PCR reaction (95‡C,
1 min denaturation; 52‡C, 50 s annealing; 72‡C, 1 min elongation for
30 cycles) using oligonucleotides from the amino- and carboxy-termini
of Rattus VEGF (sense 5P-atgaactttctgct(cg)tcttg-3P and antisense 5P-
tcaccgccttggcttgtc-3P). The PCR product was subcloned into pGEM-T
easy vector (Promega, Madison, WI, USA) and Spalax VEGF was
identi¢ed by colony hybridization using a partial Rattus VEGF
cDNA as probe. Two independent clones were sequenced in both
orientations (Weizmann Institute of Science, Rehovot, Israel). Analy-
sis and characterization of the sequence was carried out using GCG
software.
2.6. Analysis of VEGF mRNA in tissue
mRNA was prepared from tissue using RNA-Stat 60 (Tel-Test B,
Inc., USA). Quantitation of VEGF mRNA was performed by RNase
protection assay [28]. We have previously described the use of this
riboprobe for the detection of Rattus VEGF mRNA [28]. Based on
our nucleotide sequence of Spalax VEGF we were able to determine
the size of the protected fragment in the RNase protection assay using
the identical riboprobe. For Rattus VEGF mRNA a riboprobe con-
taining exons 5, 7 and 8 of Rattus VEGF will protect a 239 bp frag-
ment for VEGF isoform 165. Based on the sequence we have deter-
mined for Spalax VEGF this same riboprobe will protect a 145 bp
fragment for Spalax VEGF isoform 165. Normalization was per-
formed using 18S rRNA. Quantitation was performed using a Molec-
ular Dynamics Phosphorimager.
2.7. Data analysis
Mean þ S.E.M. values are depicted unless indicated otherwise [31].
Student’s t-test was used for comparisons between data sets and
P6 0.05 was considered signi¢cant.
3. Results
3.1. Isolation of Spalax VEGF cDNA
A full length Spalax cDNA for VEGF of the 165 amino
acid splice variant was obtained by RT-PCR of brain tissue
from the 2n = 52 species using oligonucleotides from the trans-
lational initiation and termination sites of the previously pub-
lished Rattus VEGF. The nucleotide sequence and the pre-
dicted amino acid sequence are presented in Fig. 1A. Fig.
1B depicts the amino acid sequences of VEGF of several
vertebrates from di¡erent classes. Analysis of the amino acid
sequence reveals that the percentage identity with the Spalax
VEGF is 75.8% for Xenopus, 75% for the quail, 94.7% for the
Rattus, 95.2% for the mouse, 91% for the bovine, and 91.5%
for the human. There are three amino acid substitutions
unique to Spalax and another four residues are unique to
Spalax in Rodentia.
We have used the Kimura distance [32] to generate two
phylogenetic trees (Fig. 2A,B). Fig. 2A is based on the dis-
tances between nucleic acids and Fig. 2B is based on distances
between amino acids. The method examines each pair of
aligned sequences item by item and counts the number of
exact matches, partial matches and gap symbols. If the se-
quences are nucleic acids, transitions and transversions are
also tallied. Both trees cluster mammals together separated
from amphibians (Xenopus) and birds (quail). Within mam-
mals rodents are separated from bovine and humans and
within rodents Spalax diverged earlier than the Mus from
Rattus with signi¢cantly high bootstrap values. The phyloge-
netic pattern found here is in accordance with those obtained
from hemoglobin [19,20] and ribonuclease A [33].
3.2. Qualitative measurement of blood vessel density in Spalax
and Rattus muscle and brain
We directly compared the relative microvessel density in
Fig. 2. Phylogenetic trees. The unrooted trees describe the evolu-
tionary relationship among the VEGF 165 isoform of the speci¢ed
species (S52 is Spalax ehrenbergi, 2n = 52). A: Nucleic acid tree
based on Kimura [32] two parameter distance. B: Amino acid tree
based on Kimura [32] protein distance. Both trees are derived from
the GCG software. The numbers in the junctions are bootstrapping
based on 1000 replications. The lengths of the branches are in A:
a = 23; b = 20.6; c = 24.3; d = 9; e = 28.3; f = 19.7; g = 21.1; h = 17.4;
i = 60.1; j = 108.5; k = 128.1 and in B: A = 25.7; B = 31.9; C = 27.2;
D = 13.4; E = 31.4; F = 18.3; G = 16.5; H = 9.6; I = 75.4; J = 109.3;
K = 113.5.
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Spalax skeletal muscle and brain tissue using factor VIII-re-
lated Ag immunostaining. Spalax has previously been re-
ported to demonstrate a substantially increased vascular den-
sity in skeletal muscle compared to Rattus [22]. Using a
di¡erent, well described method to quantitate vascular density
[34], we ¢nd a similar marked increase (two-fold) in vessel
density in the Spalax compared to the Rattus muscle. Using
the same procedure comparable brain sections from the Spa-
lax and Rattus failed to reveal any signi¢cant di¡erence in
vascular density. The microvessel density in the Spalax brain
was signi¢cantly lower than in the Spalax muscle. Photomi-
crographs of representative ¢elds from Spalax and Rattus
muscle and brain are shown in Fig. 3A^D.
3.3. Measurement of VEGF mRNA in Spalax and Rattus under
ambient conditions
Spalax and Rattus VEGF mRNA isoforms 165 were quan-
titated by RNase protection assay (Fig. 4) [29]. We measured
Fig. 3. Factor VIII-related antigen immunohistochemically stained skeletal muscle and cerebral cortical sections (400U). Vascular endothelial
cells are stained orange red. A representative example of a stained endothelial cell is denoted with an C in panel A. An approximately two-
fold increase in endothelial cell staining is seen in Spalax skeletal muscle (A) as compared to Rattus skeletal muscle (B) (157 þ 11.7 versus
73 þ 12.8 microvessels per high power ¢eld (P6 0.05)). No signi¢cant di¡erence is seen in endothelial cell staining in Spalax cerebral cortex (C)
as compared to Rattus cerebral cortex (D) (57 þ 4.0 versus 62 þ 4.8 microvessels per high power ¢eld (P N.S.)).
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VEGF mRNA levels in muscle, brain, lung and heart tissue
under normoxic conditions (21% O2). A plot of VEGF
mRNA versus capillary density for brain, heart, lung and
muscle resulted in a linear regression with correlation coe⁄-
cient of 0.95 (Fig. 5).
3.4. Determination of the induction of VEGF mRNA in Spalax
and Rattus under conditions of hypoxia
We exposed Spalax or Rattus to conditions of controlled O2
for periods of 2.5^11 h. Rattus were near death by 4 h of 6%
O2 or 2.5 h of 3% O2. Spalax on the other hand demonstrated
no deleterious e¡ects under either 6% or 3% O2 for up to 11 h.
We found that VEGF mRNA was signi¢cantly increased by
2.2 þ 0.3 (n = 4, P6 0.05) and 1.6 þ 0.1 (n = 4, P6 0.05) times
in Rattus muscle and brain respectively. For these studies we
pooled all three chromosomal species of Spalax because no
signi¢cant di¡erences were found between the di¡erent Spalax
species studied with respect to VEGF mRNA induction by
hypoxia. We observed a 2.3 þ 0.2 (n = 12, P6 0.05) fold in-
crease in Spalax brain and a small but signi¢cant decrease
in VEGF mRNA in Spalax muscle with hypoxia of 0.7 þ 0.1
(n = 12, P6 0.05). No signi¢cant di¡erences were observed
between animals exposed to 3% or 6% O2 nor were any sig-
ni¢cant di¡erences observed in the presence of hypercapnia
(6% CO2) in addition to the hypoxia.
4. Discussion
Ecological mammalian niches which involve frequent diving
[35], living at a high altitude [36] or living in an underground
Fig. 3 (continued).
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habitat [1] all expose the animal to an environment low in
oxygen. Diving mammals are exposed to hypoxia for brief
periods followed by a return to a normoxic environment.
High altitude mammals often are limited in their vertical as-
cent and hypoxic exposure more by the availability of ad-
equate food supplies and often migrate from high altitudes
to lower altitudes in response to this need. Spalax, on the
other hand, is unique among most subterranean animals in
that it spends much of its life underground in sealed burrows
under di¡erential levels of hypoxia. The only time that it may
leave its underground territory is after weaning when the new-
borns are chased out of the mother’s territory. Moreover, at
least two of the species of Spalax studied here, the 2n = 52 and
the 2n = 58, inhabit heavy soil with up to 800 mm of rain
which dramatically limits soil ventilation and gas permeability
[1].
One strategy taken by some species for surviving prolonged
periods of hypoxia is a marked downregulation of energy
requiring processes ^ such as myocardial and skeletal muscle
contractile activity. This is manifested by a slowing of the
heart rate and motor activity and a decrease in the basal
metabolic rate of the organism [37^40]. However, mainte-
nance of normal physical activity under conditions of chronic
hypoxia requires a strategy to increase oxygen delivery to the
tissues, especially those skeletal muscles used for tunneling
and burrowing. Spalax achieves this essentially by decreasing
the di¡usion distance for oxygen in the skeletal muscle tissue
by increasing the capillary density.
Capillary growth both developmentally [24] and in response
to hypoxia [25] has been demonstrated to be critically depend-
ent on the angiogenic factor VEGF. Therefore we decided to
focus our studies on the regulation of VEGF in Rattus and
Spalax tissues. To facilitate these studies we ¢rst cloned Spa-
lax VEGF and found that it was remarkably similar to VEGF
from other rodents but with a number of unique amino acid
substitutions. Whether these substitutions result in an altered
bioactivity for the protein remains to be determined.
We then set out to ask (i) Is there a relationship between
the greater capillary density in certain Spalax tissues such as
skeletal muscle and the amount of VEGF in those tissues? (ii)
Is VEGF regulated by hypoxia in some unique way in Spalax
tissues?
We provide here a plausible molecular explanation for the
increased capillary density in Spalax skeletal muscle compared
to Rattus skeletal muscle. Taken together with our measure-
ments of VEGF mRNA in these tissues these studies show a
clear and signi¢cant correlation (r = 0.95) between the relative
levels of VEGF mRNA and the increased capillary density in
Spalax as compared to Rattus. It will be interesting and future
studies are considered to test if the ¢ndings shown here for
Spalax are present in other subterranean mammals as well as
in normoxic rodents of comparable body size and evolution-
ary distance.
VEGF is regulated by hypoxia at the level of its steady-state
mRNA [25^30]. The regulation of VEGF mRNA in hypoxic
Rattus in vivo was similar to that previously reported [41]
with a signi¢cant increase noted in all tissues examined. We
Fig. 5. Correlation between the relative blood vessel density and
VEGF mRNA levels in Spalax and Rattus skeletal muscle, lung,
heart and brain determined using Cricket Graph software. The ratio
of VEGF mRNA in Spalax as compared to Rattus in skeletal
muscle, lung, heart and brain was 1.2 þ 0.2, 0.9 þ 0.1, 0.6 þ 0.1, and
0.5 þ 0.1 respectively. The ratio of the blood vessel density in Spalax
as compared to Rattus in skeletal muscle, lung, heart and brain was
2.2 þ 0.4, 1.3 þ 0.2, 0.85 þ 0.1 and 1.0 þ 0.1 respectively. Correlation
coe⁄cient is 0.95. For determination of VEGF levels n = 4 for each
of the tissues. Determination of microvessel density in brain and
muscle is as described in the text. Values for microvessel density for
heart and lung are from Widmer et al. [13].
Fig. 4. Representative RNase protection assay (RPA) to quantitate
Spalax ehrenbergi (three chromosomal species, 2n = 52, 58 and 60)
and Rattus norvegicus VEGF mRNA. The VEGF antisense ribo-
probe will protect a 239 bp fragment from Rattus VEGF mRNA
and a 134 bp fragment from Spalax RNA. This RPA analyzes Spa-
lax and Rattus brain VEGF mRNA from animals incubated in a
closed environmental chamber containing 21% O2 (N), 6% O2 (H)
or 6% O2/6% CO2 (C). An antisense riboprobe for 18S rRNA was
used for sample normalization.
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also observed a marked increase in VEGF mRNA in brain
from hypoxic Spalax. Unexpectedly, however ,we found no
increase but rather a statistically signi¢cant decrease in skel-
etal muscle VEGF mRNA taken from Spalax subjected to
hypoxia. (A similar small but not statistically signi¢cant de-
crease with hypoxia was also observed with Spalax lung tissue
VEGF mRNA levels.) One possible explanation for why Spa-
lax muscle does not increase VEGF mRNA with hypoxia is
that in the in vivo hypoxia experiments the Spalax muscle
does not reach a hypoxic threshold for induction of VEGF
as opposed to Rattus which does reach this threshold. Con-
ceivably, this could be due to any of a number of physiolog-
ical adaptations utilized by Spalax in response to hypoxia as
enumerated earlier in Section 1. A second possibility is that
the molecular mechanisms controlling VEGF expression in
Spalax muscle are di¡erent from those in Rattus. We believe
that the ¢rst possibility is unlikely because if the in vivo hy-
poxic stress we have imposed on Spalax did not reach a hy-
poxic threshold in its skeletal muscle then we would expect to
¢nd no change in VEGF expression (levels similar to no hy-
poxic stress). However, we have reported a signi¢cant de-
crease in VEGF expression with hypoxia in Spalax muscle
suggesting that the tissue is indeed responding, albeit unex-
pectedly, to this stimulus. It should be noted that the mRNAs
for over 95% of all expressed genes are decreased in response
to hypoxia in vitro and in vivo [38]. Thus in Spalax muscle
VEGF is behaving in response to hypoxia similar to most
other genes. This would suggest a di¡erent regulatory mech-
anism for VEGF in Spalax muscle in response to hypoxia.
This hardly seems surprising in light of the fact that Spalax
muscle clearly has a di¡erent mechanism for constitutive
VEGF regulation than Rattus.
Hypoxia has been shown to induce VEGF mRNA in many
cell types via transcriptional activation [26,27,29,42] and
mRNA stabilization [25^28,43]. Determining the mechanism
for the apparent paradoxical response in Spalax is a main
focus of ongoing studies. These studies will require the cloning
of the Spalax homologues of the cis-acting sequences (i.e.
HIF-1 and HuR binding sites in Spalax VEGF mRNA) and
the trans-acting factors (i.e. HIF-1, HuR) which have been
previously shown to mediate the induction of VEGF
mRNA by hypoxia in other species and cell types [43]. We
have compared the regulation of another HIF-1-regulated
gene in both Spalax and Rattus, erythropoietin, and prelimi-
nary studies have failed to detect any di¡erences in its regu-
lation between Rattus and Spalax under normoxic or hypoxic
conditions in vivo which may suggest that changes in the
HIF-1 molecule itself do not explain the di¡erences reported
in this study. We do not know what advantage downregula-
tion of VEGF mRNA by hypoxia in Spalax skeletal muscle
might provide. Perhaps this is related to the increased vascular
permeability function [44] of VEGF which could be deleteri-
ous to a muscle that is used intensively for burrowing in times
of acute hypoxia.
Spalax has evolved multiple mechanism that have allowed
for its successful survival in a hypoxic environment. One such
mechanism exploited by Spalax principally in its skeletal
muscle is an increase in capillary density. Our studies here
with VEGF taken together with earlier results on hemoglobin
[19,20], haptoglobin [21] and myoglobin [22], open a window
to a more detailed molecular explanation for the physiological
adaptation of Spalax to hypoxia.
Molecular studies from Spalax are currently hampered by
the inability to breed Spalax in captivity. We hope that the
development of stable cell lines from Spalax tissues will allow
these studies to proceed more rapidly and to be standardized
more easily. Ultimately we believe that this information on
Spalax VEGF will be instrumental in the development of new
strategies to regulate capillary density in ischemic syndromes,
malignancies and environmental extremes such as outer space.
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